Dexcom Ventures is the corporate venture capital arm of Dexcom, Inc., a pioneer in continuous glucose monitoring technology. It invests in early-stage companies developing sensing technologies, data analytics, remote patient monitoring, and other digital health solutions adjacent to Dexcom's core business.
100% of their portfolio is in Healthcare. Their most common stage is series-a (43% of deals). Average disclosed round size is $38.8M (across 7 rounds with reported amounts).
Portfolio
5
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
Jason Halac
Managing Director, Dexcom Ventures
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Oura | Series D | $200M | Dec 2024 |
 Phenomix Sciences | Series A | $5.5M | May 2024 |
 Signos | Series B | $20M | Oct 2023 |
 Nutromics | Series A | $14M | Sep 2022 |
| Nutromics | Series B | $14M | Sep 2022 |
| Signos | Series A | $13M | Nov 2021 |
 myBiometry | Seed | $5M | — |
Top Co-Investors
Dexcom2 shared
GV2 shared
DCM Ventures2 shared
VU Venture Partners2 shared
Artesian2 shared
Fidelity Investments1 shared
Alphabet Inc.1 shared
Cheyenne Ventures1 shared
Startmate1 shared
Elevate Ventures1 shared
Labcorp1 shared
Health2047 Capital Partners1 shared
Last updated: 20 October 2026